Title : Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.

Pub. Date : 2022 Feb 11

PMID : 35205643






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selective poly (ADP-ribose) polymerase (PARP) inhibitors such as Niraparib, Olaparib, Talazoparib, Rucaparib, and Veliparib are now approved for several cancers with loss of high-fidelity double-strand break homologous recombination (HR), namely those with deleterious mutations to BRCA1/2, PALB2, and other functionally related genes. niraparib partner and localizer of BRCA2 Homo sapiens